Category: Zacks Small Cap Research
By John Vandermosten, CFANASDAQ:LPCNOn March 27, 2019, the FDA approved Clarus Therapeutics’ Jatenzo, the first oral testosterone replacement therapy (TRT) product available on the market. We see the approval of both Jatenzo and Xyosted by Antares Ph ...
By John Vandermosten, CFATSX:RVXResverlogix Corp. (TSX:RVX) reported today that it has observed the targeted 250 events in its Phase III BETonMACE trial which began in November 2015. The drug under investigation, apabetalone, is being investigated in ...
By David Bautz, PhDNASDAQ:BVXVREAD THE FULL BVXV RESEARCH REPORTBusiness UpdateUpdate on Phase 3 Clinical Trial of M-001BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) is a biopharmaceutical company developing a universal influenza vaccine (M-001) design ...
By David Bautz, PhDNASDAQ:CERCREAD THE FULL CERC RESEARCH REPORTPositive Interim Results for CERC-301 in nOHOn April 15, 2019, Cerecor, Inc. (NASDAQ:CERC) announced positive interim results for the Phase 1 study of CERC-301 in Parkinson’s Disease (PD ...
By David Bautz, PhDNASDAQ:DFFNREAD THE FULL DFFN RESEARCH REPORTBusiness UpdateData from First Eight Patients in Phase 3 GBM Trial in mid-2019Diffusion Pharmaceuticals, Inc. (NASDAQ:DFFN) is currently conducting the Phase 3 INvestigating Tsc Against ...
By Brian Marckx, CFANASDAQ:NAOVREAD THE FULL NAOV RESEARCH REPORTFiscal 2018 Results / Business UpdateNanoVibronix (NASDAQ:NAOV) filed their 10-K for the fiscal year ending December 31, 2018. Relative to the financials, revenue was $55k and $318k in ...
By Ian Gilson, PhD, CFANASDAQ:MBIIREAD THE FULL MBII RESEARCH REPORTMarrone Bio Innovations' (NASDAQ:MBII) Regalia Maxx is now on sale in Western Canada through TerraLink Horticulture, Inc.TerraLink, based in Abbotsford, British Columbia, Canada is t ...
By Lisa ThompsonNASDAQ:PIXYREAD THE FULL PIXY RESEARCH REPORTShiftPixy (NASDAQ:PIXY), again, missed our gross billings and revenue numbers for the quarter and more than compensated with its gross margin performance. We had expected the company to gen ...
By Steven Ralston, CFAOTC:MEECREAD THE FULL MEEC RESEARCH REPORTOver the last six months, the news flow from Midwest Energy Emissions (OTC:MEEC) has been significant and positive in regard to North American contracts and corporate initiatives. In ter ...
By David Bautz, PhDNASDAQ:INMBREAD THE FULL INMB RESEARCH REPORTWe are initiating coverage of INmune Bio, Inc. (NASDAQ:INMB) with a valuation of $19.00. INmune is a biopharmaceutical company focused on treatments that target the innate immune system. ...